Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 18/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 18/20 | 0.62 |
| ▸ | RELA | Q04206 | 18/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8045126 | 0.85 | NFKB1 (0.62) | NFKB1NFKB2RELA | |
| SCHEMBL3295022 | 0.84 | NFKB1 (0.48) | NFKB1NFKB2RELA | |
| Hydrochloric Acid SCHEMBL8970554 | 0.84 | NFKB1 (0.61) | NFKB1NFKB2RELA | |
| SCHEMBL633738 | 0.80 | NFKB1 (0.56) | NFKB1NFKB2RELA | |
| SCHEMBL6082388 | 0.77 | NFKB1 (0.40) | NFKB1NFKB2RELA | |
| SCHEMBL6081970 | 0.77 | NFKB1 (0.40) | NFKB1NFKB2RELA | |
| SCHEMBL6081973 | 0.77 | NFKB1 (0.40) | NFKB1NFKB2RELA | |
| SCHEMBL4902548 | 0.76 | NFKB1 (0.52) | NFKB1NFKB2RELA | |
| SCHEMBL29515062 | 0.75 | NFKB1 (0.79) | NFKB1NFKB2RELA | |
| SCHEMBL8048594 | 0.75 | NFKB1 (0.72) | NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6700001-B2 | USEFUL AS INTERMEDIATES TO DRUGS INCLUDING THOSE TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS; STEREOSPECIFIC CYCLIZATION OF AN OPTICALLY ACTIVE PHENOL COMPOUND | WYETH | 2004-03-02 | — | — | US | disclosed |
| US-6667322-B2 | Useful for treatment of diseases such as obsessive compulsive disorder, panic attacks, anxiety, sexual dysfunction, eating disorders, obesity, addictive disorders | WYETH | 2003-12-23 | — | — | US | disclosed |
| US-20030105342-A1 | Process for stereoselective synthesis of 2-hydroxymethyl chromans | WYETH | 2003-06-05 | — | — | US | disclosed |
| US-20030100579-A1 | Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole | WYETH | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105342-A1 | Process for stereoselective synthesis of 2-hydroxymethyl chromans | CYP2S1, CYP1B1, CYP1A2 | NFKB1 3725/4885NFKB2 2476/4885RELA 2997/4885 |
| US-20030100579-A1 | Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole | TPH1, HTR1D, HTR1A | NFKB1 4001/4885NFKB2 3991/4885RELA 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.